Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1983 Jun;47(6):781–789. doi: 10.1038/bjc.1983.131

An assessment of a short-term tumour chemosensitivity assay in chronic lymphocytic leukaemia.

A G Bosanquet, M C Bird, W J Price, E D Gilby
PMCID: PMC2011362  PMID: 6190492

Abstract

A 4-day tumour sensitivity assay of potential use in predicting tumour response to cytotoxic drugs has been investigated in patients with chronic lymphocytic leukaemia. The method comprised isolation of white cells from peripheral blood, drug exposure and incubation for 4 days. Drug-induced tumour cell kill was assessed by differential staining of dead and live cells such that the latter could be morphologically identified, with subsequent calculation of tumour cell viability. Concentrations of drug for use in the assay were chosen for chlorambucil (2 micrograms ml-1), 4-hydroperoxy-cyclophosphamide (2 micrograms ml-1)--which was used in vitro in place of cyclophosphamide--prednisolone (0.5 microgram ml-1) and vincristine (0.1 microgram ml-1), to give a scatter of values which was in good agreement with clinical expectations. In 21 cases where the in vitro result could be compared with the in vivo response, there were 4 true positive comparisons (sensitive in vitro, sensitive in vivo), 15 true negative comparisons (resistant both in vitro and in vivo) and 2 false positive comparisons (sensitive in vitro, resistant in vivo). A result was obtained in 86% (65/76) of samples received. The assay appears to show considerable promise as a tumour chemosensitivity test and warrants wider investigation, including prospective in vivo/in vitro correlations that could be based on the results presented here.

Full text

PDF
787

Images in this article

783Figure 1
on p.783

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alberts D. S., Chen H. S. Tabular summary of pharmacokinetic parameters relevant to in vitro drug assay. Prog Clin Biol Res. 1980;48:351–359. [PubMed] [Google Scholar]
  2. Bhuyan B. K., Loughman B. E., Fraser T. J., Day K. J. Comparison of different methods of determining cell viability after exposure to cytotoxic compounds. Exp Cell Res. 1976 Feb;97(2):275–280. doi: 10.1016/0014-4827(76)90617-0. [DOI] [PubMed] [Google Scholar]
  3. Bosanquet A. G., Gilby E. D. Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol. 1982 Apr;18(4):355–362. doi: 10.1016/0277-5379(82)90006-2. [DOI] [PubMed] [Google Scholar]
  4. Courtenay V. D., Mills J. An in vitro colony assay for human tumours grown in immune-suppressed mice and treated in vivo with cytotoxic agents. Br J Cancer. 1978 Feb;37(2):261–268. doi: 10.1038/bjc.1978.35. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Desal D. V., Ezdinli E. Z., Stutzman L. Vincristine therapy of lymphomas and chronic lymphocytic leukemia. Cancer. 1970 Aug;26(2):352–359. doi: 10.1002/1097-0142(197008)26:2<352::aid-cncr2820260217>3.0.co;2-8. [DOI] [PubMed] [Google Scholar]
  6. Durkin W. J., Ghanta V. K., Balch C. M., Davis D. W., Hiramoto R. N. A methodological approach to the prediction of anticancer drug effect in humans. Cancer Res. 1979 Feb;39(2 Pt 1):402–407. [PubMed] [Google Scholar]
  7. Hamburger A. W., Salmon S. E. Primary bioassay of human tumor stem cells. Science. 1977 Jul 29;197(4302):461–463. doi: 10.1126/science.560061. [DOI] [PubMed] [Google Scholar]
  8. Hamburger A. W. Use of in vitro tests in predictive cancer chemotherapy. J Natl Cancer Inst. 1981 Jun;66(6):981–988. doi: 10.1093/jnci/66.6.981. [DOI] [PubMed] [Google Scholar]
  9. Han T., Ezdinli E. Z., Shimaoka K., Desai D. V. Chlorambucil vs. combined chlorambucil-corticosteroid therapy in chronic lymphocytic leukemia. Cancer. 1973 Mar;31(3):502–508. doi: 10.1002/1097-0142(197303)31:3<502::aid-cncr2820310303>3.0.co;2-7. [DOI] [PubMed] [Google Scholar]
  10. Liepman M., Votaw M. L. The treatment of chronic lymphocytic leukemia with COP chemotherapy. Cancer. 1978 May;41(5):1664–1669. doi: 10.1002/1097-0142(197805)41:5<1664::aid-cncr2820410503>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
  11. Nelson R. L., Dyke R. W., Root M. A. Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treat Rev. 1980 Sep;7 (Suppl 1):17–24. doi: 10.1016/s0305-7372(80)80003-x. [DOI] [PubMed] [Google Scholar]
  12. Oken M. M., Kaplan M. E. Combination chemotherapy with cyclophosphamide, vincristine, and prednisone in the treatment of refractory chronic lymphocytic leukemia. Cancer Treat Rep. 1979 Mar;63(3):441–447. [PubMed] [Google Scholar]
  13. Rai K. R., Sawitsky A., Cronkite E. P., Chanana A. D., Levy R. N., Pasternack B. S. Clinical staging of chronic lymphocytic leukemia. Blood. 1975 Aug;46(2):219–234. [PubMed] [Google Scholar]
  14. Roper P. R., Drewinko B. Cell survival following treatment with antitumor drugs. Cancer Res. 1979 Apr;39(4):1428–1430. [PubMed] [Google Scholar]
  15. Roper P. R., Drewinko B. Comparison of in vitro methods to determine drug-induced cell lethality. Cancer Res. 1976 Jul;36(7 Pt 1):2182–2188. [PubMed] [Google Scholar]
  16. Salmon S. E., Alberts D. S., Durie B. G., Meyskens F. L., Jones S. E., Soehnlen B., Chen H. S., Moon T. Clinical correlations of drug sensitivity in the human tumor stem cell assay. Recent Results Cancer Res. 1980;74:300–305. doi: 10.1007/978-3-642-81488-4_36. [DOI] [PubMed] [Google Scholar]
  17. Salmon S. E., Hamburger A. W., Soehnlen B., Durie B. G., Alberts D. S., Moon T. E. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N Engl J Med. 1978 Jun 15;298(24):1321–1327. doi: 10.1056/NEJM197806152982401. [DOI] [PubMed] [Google Scholar]
  18. Salmon S. E., Meyskens F. L., Jr, Alberts D. S., Soehnlen B., Young L. New drugs in ovarian cancer and malignant melanoma: in vitro phase II screening with the human tumor stem cell assay. Cancer Treat Rep. 1981 Jan-Feb;65(1-2):1–12. [PubMed] [Google Scholar]
  19. Sawitsky A., Rai K. R., Glidewell O., Silver R. T. Comparison of daily versus intermittent chlorambucil and prednisone therapy in the treatment of patients with chronic lymphocytic leukemia. Blood. 1977 Dec;50(6):1049–1059. [PubMed] [Google Scholar]
  20. Tannock I. Cell kinetics and chemotherapy: a critical review. Cancer Treat Rep. 1978 Aug;62(8):1117–1133. [PubMed] [Google Scholar]
  21. Volm M., Wayss K., Kaufmann M., Mattern J. Pretherapeutic detection of tumour resistance and the results of tumour chemotherapy. Eur J Cancer. 1979 Jul;15(7):983–993. doi: 10.1016/0014-2964(79)90282-2. [DOI] [PubMed] [Google Scholar]
  22. Von Hoff D. D., Casper J., Bradley E., Sandbach J., Jones D., Makuch R. Association between human tumor colony-forming assay results and response of an individual patient's tumor to chemotherapy. Am J Med. 1981 May;70(5):1027–1041. doi: 10.1016/0002-9343(81)90859-7. [DOI] [PubMed] [Google Scholar]
  23. Von Hoff D. D., Weisenthal L. In vitro methods to predict for patient response to chemotherapy. Adv Pharmacol Chemother. 1980;17:133–156. doi: 10.1016/s1054-3589(08)60009-5. [DOI] [PubMed] [Google Scholar]
  24. Weisenthal L. M., Dill P. L., Kurnick N. B., Lippman M. E. Comparison of dye exclusion assays with a clonogenic assay in the determination of drug-induced cytotoxicity. Cancer Res. 1983 Jan;43(1):258–264. [PubMed] [Google Scholar]
  25. Weisenthal L. M. In vitro assays in preclinical antineoplastic drug screening. Semin Oncol. 1981 Dec;8(4):362–376. [PubMed] [Google Scholar]
  26. Weisenthal L. M., Marsden J. A., Dill P. L., Macaluso C. K. A novel dye exclusion method for testing in vitro chemosensitivity of human tumors. Cancer Res. 1983 Feb;43(2):749–757. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES